Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Hepatic insulin signalling involves insulin receptor substrates (Irs) 1/2, and is normally associated with the inhibition of gluconeogenesis and activation of lipogenesis. In diabetes and obesity, insulin no longer suppresses hepatic gluconeogenesis, while continuing to activate lipogenesis, a state referred to as ‘selective insulin resistance’. Here, we show that ‘selective insulin resistance’ is caused by the differential expression of Irs1 and Irs2 in different zones of the liver. We demonstrate that hepatic Irs2-knockout mice develop ‘selective insulin resistance’, whereas mice lacking in Irs1, or both Irs1 and Irs2, develop ‘total insulin resistance’. In obese diabetic mice, Irs1/2-mediated insulin signalling is impaired in the periportal zone, which is the primary site of gluconeogenesis, but enhanced in the perivenous zone, which is the primary site of lipogenesis. While hyperinsulinaemia reduces Irs2 expression in both the periportal and perivenous zones, Irs1 expression, which is predominantly in the perivenous zone, remains mostly unaffected. These data suggest that ‘selective insulin resistance’ is induced by the differential distribution, and alterations of hepatic Irs1 and Irs2 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SREBP1c, which is controlled by both insulin signaling and insulin-independent pathways [2,20,75]”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The concept of hepatic zonation of insulin signaling components can also help explain the paradoxical coexistence of increased hepatic glucose output and increased hepatic lipogenesis in MASLD [15,20].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Studies suggest that IRS1 and IRS2 have distinct roles in regulating hepatic lipid metabolism [20,30,97].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, DNL is markedly decreased in LIRS1KO mice but not in LIRS2KO mice.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“This leads to impaired insulin signaling in gluconeogenic zones, resulting in insufficient suppression of HGP and thus contributing to systemic hyperglycemia.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80210-5 · Cited by 1,342
Self-citationMichael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A., & Kahn, C. R. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00015-8 · Cited by 1,296
Postic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204
Selective versus Total Insulin Resistance: A Pathogenic Paradox
Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 965
SHIMOMURA, I. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00009-5 · Cited by 855
Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., & Goldstein, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118951 · Cited by 816
Research works printed but not linked: 1
- Benhamouche, S. et al. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev. Cell. 10, 759–770 (2006). · DOI · Paper page
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
The PI3K/AKT Pathway in Obesity and Type 2 Diabetes
Huang, X., Liu, G., Guo, J., & Su, Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27173 · Cited by 1,673
“And recent study finds Irs2-knockout mice develop ‘selective insulin resistance’, whereas mice lacking in Irs1, or both Irs1 and Irs2, develop ‘total insulin resistance’, which indicates the IRS 1/2 are the cause of insulin selective resistance [109]; in the second, hepatic insulin signalling remains intact but the ce…”
BackgroundSREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology
Shimano, H., & Sato, R. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.91 · Cited by 1,174
Biochemical and cellular properties of insulin receptor signalling
Haeusler, R. A., McGraw, T. E., & Accili, D. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.89 · Cited by 739
Pathophysiology of Diabetic Dyslipidemia
Hirano, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17023 · Cited by 552
Metadata
- Authors
- Kubota, N., Kubota, T., Kajiwara, E., Iwamura, T., Kumagai, H., Watanabe, T., Inoue, M., Takamoto, I., Sasako, T., Kumagai, K., Kohjima, M., Nakamuta, M., Moroi, M., Sugi, K., Noda, T., Terauchi, Y., Ueki, K., & Kadowaki, T.
- Affiliations
- National Institute of Biomedical Innovation, Health and Nutrition (JP)
- Toho University (JP)
- The University of Tokyo (JP)
- Hokkaido University (JP)
- Tokyo Medical University (JP)
- National Kyushu Medical Center (JP)
- Japanese Foundation For Cancer Research (JP)
- Yokohama City University (JP)
- Corresponding author
- Kubota, Naoto
- Kadowaki, Takashi
- ORCID
- Venue
- Nature Communications
- Published
- 2016-10-06
- Volume
- 7
- Issue
- 1
- Pages
- 12977-12977
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5059684
- OpenAlex
- W2529090544
- Cited by
- 143
- References
- 46
- Citations by year
- 2026: 22 · 2025: 19 · 2024: 17 · 2023: 19 · 2022: 11 · 2021: 17 · 2020: 15 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 1
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Takeda Science Foundation
- Ministry of Education, Culture, Sports, Science and Technology (20229008, 18209033, 19591037, 16209030, 21390279)
- Ono Medical Research Foundation
- Japan Society for the Promotion of Science (16K15488, 16H05329, 26000012)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- IRS-1, insulin receptor substrate 2, liver zonation, periportal zone, perivenous zone, gluconeogenesis, lipogenesis, hyperinsulinemia, obesity, diabetes mellitus
- MeSH terms
- Animals, Cell Nucleus, Diabetes Mellitus, Diabetes Mellitus, Experimental, Gluconeogenesis, Homeostasis, Humans, Hyperinsulinism, Insulin, Insulin Resistance, Liver, Male, Mice, Inbred C57BL, Obesity, Receptor, Insulin, Signal Transduction, Antigens, CD, Mice, Knockout, Mice, Insulin Receptor Substrate Proteins, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.